Sanofi faces $250M charge after J&J-partnered vaccine flunks late-stage test

Sanofi has been hit with a $250 million impairment charge after an E. coli vaccine candidate it was developing with Johnson & Johnson failed to clear a Phase 3 study. An independent data monitoring committee ...